# Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

> **NCT00951574** · PHASE3 · COMPLETED · sponsor: **Italfarmaco** · enrollment: 1166 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Nadroparin calcium
- **DRUG:** saline solution (placebo)

## Key facts

- **NCT ID:** NCT00951574
- **Lead sponsor:** Italfarmaco
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2007-05
- **Final completion:** 2008-07
- **Target enrollment:** 1166 (ACTUAL)
- **Last updated:** 2012-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951574, "Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00951574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*